<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463071</url>
  </required_header>
  <id_info>
    <org_study_id>D5884C00002</org_study_id>
    <nct_id>NCT02463071</nct_id>
  </id_info>
  <brief_title>AZD0585 Phase III Long-term Study in Japan</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised, double-blind phase III long-term study to evaluate efficacy and
      safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients
      with hyperlipidemia accompanied by hypertriglyceridemia .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2015</start_date>
  <completion_date type="Actual">March 11, 2017</completion_date>
  <primary_completion_date type="Actual">March 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent change in serum triglycerides</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To demonstrate the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) in Japanese patients with hypertriglyceridemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD0585 by assessment of adverse events in patients</measure>
    <time_frame>From baseline to Week52</time_frame>
    <description>To evaluate the long-term (up to 52 weeks) safety of AZD0585 in Japanese patients with hypertriglyceridemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD0585 by assessment of physical findings in patients</measure>
    <time_frame>From baseline to Week52</time_frame>
    <description>To evaluate the long-term (up to 52 weeks) safety of AZD0585 in Japanese patients with hypertriglyceridemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD0585 by assessment of vital signs in patients</measure>
    <time_frame>From baseline to Week52</time_frame>
    <description>To evaluate the long-term (up to 52 weeks) safety of AZD0585 in Japanese patients with hypertriglyceridemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD0585 by assessment of laboratory data in patients</measure>
    <time_frame>From baseline to Week52</time_frame>
    <description>To evaluate the long-term (up to 52 weeks) safety of AZD0585 in Japanese patients with hypertriglyceridemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent change in serum lipid profile</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil). The serum lipid profile includes total cholesterol, High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol,Very low-density lipoprotein cholesterol and Non-high-density lipoprotein cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in plasma fatty acids profile.</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) . The plasma fatty acids profile includes eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid and eicosapentaenoic acid per arachidonic acid rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in apolipoproteins profile</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) . Apolipoproteins include Apolipoprotein A-I, Apolipoprotein A-II, Apolipoprotein B, Apolipoprotein B48, Apolipoprotein C-II, Apolipoprotein C-III and Apolipoprotein E.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in Lipoprotein(a)</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in Remnant like particles cholesterol</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in Proprotein Convertase Subtilisin Kexin 9</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in high sensitivity C-reactive protein</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in Low-density lipoprotein per Apolipoprotein B ratio</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AZD0585 by assessment of percent changes in small dense low-density lipoprotein.</measure>
    <time_frame>From baseline to Week12</time_frame>
    <description>To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">886</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>AZD0585 2g group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD0585 4g group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0585 1g × 4 capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AZD0585 placebo 1g × 4 capsules once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0585</intervention_name>
    <description>1g soft capsule</description>
    <arm_group_label>AZD0585 2g group</arm_group_label>
    <arm_group_label>AZD0585 4g group</arm_group_label>
    <other_name>Epanova</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0585 placebo</intervention_name>
    <description>1g soft capsule</description>
    <arm_group_label>AZD0585 2g group</arm_group_label>
    <arm_group_label>Placebo control group</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Japanese men or women, ≥20 years of age.

          -  Subjects must meet all of the following criteria;

               1. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range
                  150 - 499 mg/dL

               2. %TG change between Visit 2 and Visit 3 must be within 30%

               3. %LDL-C change between Visit 2 and Visit 3 must be within 25%

        Key Exclusion Criteria:

          -  Allergy or intolerance to omega-3 fatty acids and omega-3-acid ethyl esters.

          -  Known lipoprotein lipase impairment or deficiency, or Apolipoprotein C-II deficiency
             or familial dysbetalipoproteinemia.

          -  Current or history of pancreatitis.

          -  Type I diabetes mellitus, use of insulin, or haemoglobin A1c &gt;10% at Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kayoko Ikeda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Social medial corporation Koyokai Nakajima Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aki-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chofu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Funabashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itami-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naha-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urasoe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

